These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 9923574)

  • 1. Assessment of the value of therapeutic monitoring of tacrine in Alzheimer's disease.
    Roberts CJ; Ford JM; Truman CA; Scott M; Mäkelä PM; Wilcock GK
    Eur J Clin Pharmacol; 1998; 54(9-10):721-4. PubMed ID: 9923574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Key methodological features of randomized controlled trials of Alzheimer's disease therapy. Minimal clinically important difference, sample size and trial duration.
    Burback D; Molnar FJ; St John P; Man-Son-Hing M
    Dement Geriatr Cogn Disord; 1999; 10(6):534-40. PubMed ID: 10559571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of estrogen replacement therapy on response to tacrine in patients with Alzheimer's disease.
    Schneider LS; Farlow MR; Henderson VW; Pogoda JM
    Neurology; 1996 Jun; 46(6):1580-4. PubMed ID: 8649552
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Guidelines for the use of tacrine in Alzheimer's disease: clinical application and effectiveness. Johns Hopkins Dementia Research Clinic.
    Lyketsos CG; Corazzini K; Steele CD; Kraus MF
    J Neuropsychiatry Clin Neurosci; 1996; 8(1):67-73. PubMed ID: 8845704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Responder characteristics to a single oral dose of cholinesterase inhibitor: a double-blind placebo-controlled study with tacrine in Alzheimer patients.
    Almkvist O; Jelic V; Amberla K; Hellström-Lindahl E; Meurling L; Nordberg A
    Dement Geriatr Cogn Disord; 2001; 12(1):22-32. PubMed ID: 11125238
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WITHDRAWN: Tacrine for Alzheimer's disease.
    Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
    Cochrane Database Syst Rev; 2007 Jul; (3):CD000202. PubMed ID: 17636619
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group.
    Davis KL; Thal LJ; Gamzu ER; Davis CS; Woolson RF; Gracon SI; Drachman DA; Schneider LS; Whitehouse PJ; Hoover TM
    N Engl J Med; 1992 Oct; 327(18):1253-9. PubMed ID: 1406817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steady-state pharmacokinetics of tacrine in patients with Alzheimer's disease.
    Cutler NR; Sedman AJ; Prior P; Underwood BA; Selen A; Balogh L; Kinkel AW; Gracon SI; Gamzu ER
    Psychopharmacol Bull; 1990; 26(2):231-4. PubMed ID: 2236461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and efficacy of idebenone versus tacrine in patients with Alzheimer's disease: results of a randomized, double-blind, parallel-group multicenter study.
    Gutzmann H; Kühl KP; Hadler D; Rapp MA
    Pharmacopsychiatry; 2002 Jan; 35(1):12-8. PubMed ID: 11819153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed-model analysis of incomplete longitudinal data from a high-dose trial of tacrine (Cognex) in Alzheimer's patients.
    Smith F
    J Biopharm Stat; 1996 Mar; 6(1):59-67. PubMed ID: 8838779
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential neuropsychiatric symptom responses to tacrine in Alzheimer's disease: relationship to dementia severity.
    Kaufer D; Cummings JL; Christine D
    J Neuropsychiatry Clin Neurosci; 1998; 10(1):55-63. PubMed ID: 9547467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tacrine for Alzheimer's disease.
    Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
    Cochrane Database Syst Rev; 2000; (3):CD000202. PubMed ID: 10908463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An enriched-population, double-blind, placebo-controlled, crossover study of tacrine and lecithin in Alzheimer's disease. The Tacrine 970-6 Study Group.
    Foster NL; Petersen RC; Gracon SI; Lewis K
    Dementia; 1996; 7(5):260-6. PubMed ID: 8872417
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease.
    Wagstaff AJ; McTavish D
    Drugs Aging; 1994 Jun; 4(6):510-40. PubMed ID: 7521234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The apolipoprotein E epsilon4 allele and the response to tacrine therapy in Alzheimer's disease.
    Rigaud AS; Traykov L; Caputo L; Guelfi MC; Latour F; Couderc R; Moulin F; de Rotrou J; Forette F; Boller F
    Eur J Neurol; 2000 May; 7(3):255-8. PubMed ID: 10886308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease.
    Doody RS; Dunn JK; Clark CM; Farlow M; Foster NL; Liao T; Gonzales N; Lai E; Massman P
    Dement Geriatr Cogn Disord; 2001; 12(4):295-300. PubMed ID: 11351141
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability and pharmacokinetic disposition of tacrine in elderly patients with Alzheimer's disease.
    Lou G; Montgomery PR; Sitar DS
    J Psychiatry Neurosci; 1996 Nov; 21(5):334-9. PubMed ID: 8973053
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of tacrine on behavioral symptoms in Alzheimer's disease: an open-label study.
    Kaufer DI; Cummings JL; Christine D
    J Geriatr Psychiatry Neurol; 1996 Jan; 9(1):1-6. PubMed ID: 8679057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tacrine in Alzheimer's disease: pharmacokinetic and clinical comparison of oral and rectal administration.
    Ahlin A; Hassan M; Junthé T; Nybäck H
    Int Clin Psychopharmacol; 1994; 9(4):263-70. PubMed ID: 7868848
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of drugs for Alzheimer's disease.
    Parnetti L
    Clin Pharmacokinet; 1995 Aug; 29(2):110-29. PubMed ID: 7586900
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.